Operating Metrics 營運指標
Novartis AG (NVS) Operating Metrics 營運指標
Novartis AG NVS 最近 8 季公司營運 KPI、指標定義、跨期趨勢與官方來源。
資料截至：2026-06-30
最新營運指標
- Kisqali Sales
- $5.861B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Kesimpta Sales
- $5.038B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Cosentyx Sales
- $6.895B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Pluvicto Sales
- $2.462B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Leqvio Sales
- $1.575B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Kesimpta Patients Treated Since Launch
- >216 K patients · 2026-06-30 來源：Novartis AG
季度趨勢
| 指標 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|---|---|---|---|
| Kisqali Sales | $1.695B | $1.516B | $1.321B | $1.329B | $1.177B | $0.956B | $0.902B | $0.787B |
| Kesimpta Sales | $1.424B | $1.164B | $1.228B | $1.222B | $1.077B | $0.899B | $0.950B | $0.838B |
| Cosentyx Sales | $1.824B | $1.566B | $1.807B | $1.698B | $1.629B | $1.534B | $1.596B | $1.693B |
| Pluvicto Sales | $0.651B | $0.642B | $0.605B | $0.564B | $0.454B | $0.371B | $0.351B | $0.386B |
| Leqvio Sales | $0.480B | $0.452B | $0.335B | $0.308B | $0.298B | $0.257B | $0.223B | $0.198B |
| Kesimpta Patients Treated Since Launch | >216 K patients | >200 K patients | >187 K patients | >155 K patients | — | — | — | — |
資料來源
- Novartis Q2 2026 Condensed Interim Financial Report – Supplementary Data · Novartis AG · 2026-07-21
- Novartis Q1 2026 Condensed Interim Financial Report – Supplementary Data · Novartis AG · 2026-04-28
- Novartis Q4 2025 Condensed Financial Report – Supplementary Data · Novartis AG · 2026-02-04
- Novartis Q3 2025 Condensed Interim Financial Report – Supplementary Data · Novartis AG · 2025-10-28